Ocular Surface Disease clinical trials at UC Health
1 research study open to new patients
open to eligible people ages 18 years and up
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).